UB Paderborn / Katalog / Suche / in CDI

BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition

Cancer discovery, 2021-01, Vol.11 (1), p.142-157

2021

Link zum Volltext

Verfügbarkeit prüfen

Efficient and Scalable One-Pot Synthesis of 2,4-Dienols from Cycloalkenones: Optimized Total Synthesis of Valerenic Acid

Organic letters, 2011-10, Vol.13 (19), p.5310-5313

2011

Link zum Volltext

Verfügbarkeit prüfen

Synthesis of the Lycopodium Alkaloid (+)-Lycoflexine

Journal of the American Chemical Society, 2010-10, Vol.132 (41), p.14338-14339

2010

Link zum Volltext

Verfügbarkeit prüfen

From Planning to Optimization: Total Synthesis of Valerenic Acid and Some Bioactive Derivatives

European journal of organic chemistry, 2012-04, Vol.2012 (10), p.2041-2053

2012

Link zum Volltext

Verfügbarkeit prüfen

opnMe.com: a digital initiative for sharing tools with the biomedical research community

Nature reviews. Drug discovery, 2022-07, Vol.21 (7), p.475-476

2022

Link zum Volltext

Verfügbarkeit prüfen

Synthesis of MDM2-p53 Inhibitor BI-0282 via a Dipolar Cycloaddition and Late-Stage Davis–Beirut Reaction

Organic process research & development, 2022-08, Vol.26 (8), p.2526-2531

2022

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Novel Spiro[3H‑indole-3,2′-pyrrolidin]-2(1H)‑one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2–p53 Interaction

Journal of medicinal chemistry, 2016-11, Vol.59 (22), p.10147-10162

2016

Link zum Volltext

Verfügbarkeit prüfen

Total Synthesis of Valerenic Acid, a Potent GABA A Receptor Modulator

Organic letters, 2009-03, Vol.11 (5), p.1151-1153

2009

Link zum Volltext

Verfügbarkeit prüfen

Abstract 1091: BI-3406 and BI 1701963: Potent and selective SOS1::KRAS inhibitors induce regressions in combination with MEK inhibitors or irinotecan

Cancer research (Chicago, Ill.), 2020-08, Vol.80 (16_Supplement), p.1091-1091

2020

Link zum Volltext

Verfügbarkeit prüfen

Abstract LB003: BI 907828: A highly potent MDM2-p53 antagonist suitable for intermittent dose schedules

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.LB003-LB003

2023

Link zum Volltext

Verfügbarkeit prüfen

ChemInform Abstract: Efficient and Scalable One-Pot Synthesis of 2,4-Dienols from Cycloalkenones: Optimized Total Synthesis of Valerenic Acid

ChemInform, 2012-02, Vol.43 (6), p.no-no

2012

Link zum Volltext

Verfügbarkeit prüfen

ChemInform Abstract: Total Synthesis of Valerenic Acid (VII), a Potent GABAA Receptor Modulator

ChemInform, 2009-07, Vol.40 (30), p.no-no

2009

Link zum Volltext

Verfügbarkeit prüfen

ChemInform Abstract: Total Synthesis of Valerenic Acid (VII), a Potent GABA A Receptor Modulator

ChemInform, 2009-07, Vol.40 (30)

2009

Link zum Volltext

Verfügbarkeit prüfen

Randomized Controlled Trial of Fosmidomycin-Clindamycin versus Sulfadoxine-Pyrimethamine in the Treatment of Plasmodium falciparum Malaria

Antimicrobial Agents and Chemotherapy, 2007-05, Vol.51 (5), p.1869-1871

2007

Link zum Volltext

Verfügbarkeit prüfen

Determinants of post-malarial anemia in African children treated with parenteral artesunate

Scientific reports, 2019-12, Vol.9 (1), p.18134-8, Article 18134

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract PL06-01: Discovery of BI-3406: A potent and selective SOS1::KRAS inhibitor opens a new approach for treating KRAS-driven tumors

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.PL06-01-PL06-01

2019

Link zum Volltext

Verfügbarkeit prüfen

Abstract C133: Effective targeting of KRAS-driven tumors by the first-in-class, orally bioavailable SOS1::KRAS inhibitor BI-3406

Molecular cancer therapeutics, 2019-12, Vol.18 (12_Supplement), p.C133-C133

2019

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

BI-3406, a Potent and Selective SOS1-KRAS Interaction Inhibitor, Is Effective in KRAS-Driven Cancers through Combined MEK Inhibition

Efficient and Scalable One-Pot Synthesis of 2,4-Dienols from Cycloalkenones: Optimized Total Synthesis of Valerenic Acid

Synthesis of the Lycopodium Alkaloid (+)-Lycoflexine

From Planning to Optimization: Total Synthesis of Valerenic Acid and Some Bioactive Derivatives

opnMe.com: a digital initiative for sharing tools with the biomedical research community

Synthesis of MDM2-p53 Inhibitor BI-0282 via a Dipolar Cycloaddition and Late-Stage Davis–Beirut Reaction

Discovery of Novel Spiro[3H‑indole-3,2′-pyrrolidin]-2(1H)‑one Compounds as Chemically Stable and Orally Active Inhibitors of the MDM2–p53 Interaction

Total Synthesis of Valerenic Acid, a Potent GABA A Receptor Modulator

One Atom Makes All the Difference: Getting a Foot in the Door between SOS1 and KRAS

Abstract 1091: BI-3406 and BI 1701963: Potent and selective SOS1::KRAS inhibitors induce regressions in combination with MEK inhibitors or irinotecan

Abstract LB003: BI 907828: A highly potent MDM2-p53 antagonist suitable for intermittent dose schedules

Targeted Synthesis of Complex Spiro[3H‐indole‐3,2′‐pyrrolidin]‐2(1H)‐ones by Intramolecular Cyclization of Azomethine Ylides: Highly Potent MDM2–p53 Inhibitors

ChemInform Abstract: Efficient and Scalable One-Pot Synthesis of 2,4-Dienols from Cycloalkenones: Optimized Total Synthesis of Valerenic Acid

ChemInform Abstract: Total Synthesis of Valerenic Acid (VII), a Potent GABAA Receptor Modulator

ChemInform Abstract: Total Synthesis of Valerenic Acid (VII), a Potent GABA A Receptor Modulator

Randomized Controlled Trial of Fosmidomycin-Clindamycin versus Sulfadoxine-Pyrimethamine in the Treatment of Plasmodium falciparum Malaria

Determinants of post-malarial anemia in African children treated with parenteral artesunate

Abstract PL06-01: Discovery of BI-3406: A potent and selective SOS1::KRAS inhibitor opens a new approach for treating KRAS-driven tumors

Abstract C133: Effective targeting of KRAS-driven tumors by the first-in-class, orally bioavailable SOS1::KRAS inhibitor BI-3406

Suchergebnisse filtern